The effect of case management on childhood pneumonia mortality in developing countries by Theodoratou, Evropi et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The effect of case management on childhood pneumonia
mortality in developing countries
Citation for published version:
Theodoratou, E, Al-Jilaihawi, S, Woodward, F, Ferguson, J, Jhass, A, Ballet, M, Kolcic, I, Sadruddin, S,
Duke, T, Rudan, I & Campbell, H 2010, 'The effect of case management on childhood pneumonia mortality
in developing countries' International Journal of Epidemiology, vol. 39, pp. 155-171. DOI:
10.1093/ije/dyq032
Digital Object Identifier (DOI):
10.1093/ije/dyq032
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
International Journal of Epidemiology
Publisher Rights Statement:
    Published by Oxford University Press on behalf of the International Epidemiological Association © The Author
2010; all rights reserved.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use,
distribution, and reproduction in any medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
The effect of case management on
childhood pneumonia mortality
in developing countries
Evropi Theodoratou,1y Sarah Al-Jilaihawi,1y Felicity Woodward,1y Joy Ferguson,1y Arnoupe Jhass,1
Manuela Balliet,1 Ivana Kolcic,2 Salim Sadruddin,3 Trevor Duke,4 Igor Rudan1,5 and
Harry Campbell1
1Public Health Sciences, University of Edinburgh, Edinburgh, UK, 2Andrija Stampar School of Public Health, Medical School,
University of Zagreb, Zagreb, Croatia, 3Save the Children, Washington DC, USA, 4Centre for International Child Health,
University of Melbourne, Melbourne, Australia and 5Croatian Centre for Global Health, Medical School, University of Split,
Split, Croatia
Corresponding author. Public Health Sciences, College of Medicine and Vet Medicine, University of Edinburgh, Teviot Place,
Edinburgh EH8 9AG, UK.
E-mail: harry.campbell@ed.ac.uk,
yThese authors contributed equally to this work.
Background With the aim of populating the Lives Saved Tool (LiST) with
parameters of effectiveness of existing interventions, we conducted
a systematic review of the literature assessing the effect of pneu-
monia case management on mortality from childhood pneumonia.
Methods This review covered the following interventions: community case
management with antibiotic treatment, and hospital treatment
with antibiotics, oxygen, zinc and vitamin A. Pneumonia mortality
outcomes were sought where available but data were also recorded
on secondary outcomes. We summarized results from randomized
controlled trials (RCTs), cluster RCTs, quasi-experimental studies
and observational studies across outcome measures using standard
meta-analysis methods and used a set of standardized rules devel-
oped for the purpose of populating the LiST with required param-
eters, which dealt with the issues of comparability of the studies in
a uniform way across a spectrum of childhood conditions.
Results We estimate that community case management of pneumonia
could result in a 70% reduction in mortality from pneumonia in
0–5-year-old children. In contrast treatment of pneumonia episodes
with zinc and vitamin A is ineffective in reducing pneumonia mor-
tality. There is insufficient evidence to make a quantitative estimate
of the effect of hospital case management on pneumonia mortality
based on the published data.
Conclusion The available evidence reinforces the effectiveness of community
and hospital case management with World Health Organization-
recommended antibiotics and the lack of effect of zinc and vitamin
A supportive treatment for children with pneumonia. Evidence
from one trial demonstrates the effectiveness of oxygen therapy
but further research is required to give higher quality evidence so
that an effect estimate can be incorporated into the LiST model.
We identified no trials that separately evaluated the effectiveness of
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other supportive care interventions. The summary estimates of
effect on pneumonia mortality will inform the LiST model.
Keywords childhood pneumonia, case management, community, hospital,
developing countries
Background
According to a UNICEF–World Health Organization
(WHO) report from 2006, over 2 million children die
from pneumonia each year, accounting for almost one
in five under-5 deaths worldwide.1 Globally, the esti-
mated incidence of clinical pneumonia in children
aged <5 years in developing countries is 0.28 episodes
per child-year, whereas in developed countries it is
0.05 episodes per child-year.2,3 Thus, 155 million
episodes of clinical pneumonia occur in children
<5 years of age annually.
As part of the primary care approach, children with
pneumonia require access to good-quality basic
first-level care (community case management).4
Based on current WHO guidelines it has been esti-
mated that 10% of children presenting with pneu-
monia, i.e. those with severe or very severe
pneumonia, may require referral to a first referral or
district hospital for hospital treatment. Since pneumo-
nia is the leading cause of death in children <5 years
of age, interventions to promote the prevention and
treatment of pneumonia are an essential part of child
survival efforts to achieve Millennium Development
Goal 4.
Previous reviews by Sazawal and Black have studied
the effect of community case management on pneu-
monia mortality and overall child mortality.5,6 This
article reviews a wider range of case management
interventions and was conducted in a standard
manner (adopted for a review of all child health inter-
ventions) following guidelines set by the Child Health
Epidemiology reference Group (CHERG). The overall
aim is to provide parameters needed for the Lives
Saved Tool (LiST) software to model the preventable
deaths childhood pneumonia and to document all
steps of this process in a transparent manner, thus
assisting the wider acceptance of the LiST tool.
Methods
Identification and selection of studies
We attempted to identify all randomized controlled
trials (RCTs), cluster RCTs (cRCTs), quasi-
experimental studies and observational studies inves-
tigating the effect of community and hospital case
management on pneumonia mortality and other
pneumonia-related outcomes in children <5 years
old. Studies were identified from the following data-
bases: Medline (1970 to August 2008), EMBASE
(1970 to August 2008) and the Web of Knowledge
(1970 to August 2008; only for the community case
management review). Details of the exact search stra-
tegies used to identify relevant studies for (i) the
community case management and (ii) hospital case
management [including (a) antibiotic treatment for
(very) severe pneumonia, (b) oxygen treatment, (c)
treatment with zinc supplements and (d) treatment
with vitamin A supplements are presented in
Supplementary Tables S1 and S2]. In addition, rele-
vant studies were identified by searching the refer-
ences of the selected studies. Eligible studies were
selected according to the pre-determined inclusion
criteria.7 In particular: (i) included studies (a) were
RCTs, cRCTs, quasi-RCTs or observational studies and
(b) had a control arm of placebo or no treatment;
(ii) children of included studies were (a) <5 years
old, (b) were followed up until 52 years of age
(in experimental studies; not applicable for the
case–control studies) and (c) had a clear case defini-
tion consistent with pneumonia.2
Due to the nature of the hospital-based interven-
tions under review, no RCTs were identified as it
would not be ethical to conduct such studies.
Therefore observational studies were sought according
to the following inclusion criteria: developing country
setting; clear case definition of pneumonia (severe or
very severe as defined by WHO); children <5 years of
age; sample size of 100 or more; intervention is well
defined (in terms of dose, administration, frequency
of delivery). The following exclusion criteria were
applied: ambulatory treatment for non-severe pneu-
monia; no data on deaths available; selective groups
of preschool children [e.g. malnourished, human
immunodeficiency virus (HIV) positive, specific pneu-
monia pathogens isolated) studied (Supplementary
Table S3)].
The main types of outcome measures for community
case management were: pneumonia-specific mortality,
all-cause mortality and incidence of moderate or
severe episodes of acute lower respiratory infection
(ALRI). The main outcomes for the hospital case
management studies were (i) for antibiotic treatment
studies: intervention case fatality ratios and treatment
failure rates; (ii) for oxygen treatment study: all-cause
mortality of children with pneumonia; (iii) for studies
of zinc supplement treatment: length of hospitaliza-
tion, time to resolution of severe illness, lethargy,
inability to eat, low oxygen saturation, chest indraw-
ing and tachypnoea; and (iv) for studies of vitamin A
supplement treatment: all-cause mortality of children
with pneumonia, length of hospitalization and time to
resolution of low oxygen saturation and tachypnoea.
There were no language or publication restrictions.
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One original and one parallel review were conducted
by independent investigators and results from the
two searches and study selections were compared
and merged.
Abstraction, quality assessment and
meta-analyses
Data from all studies that met final inclusion and
exclusion criteria were abstracted into a standardized
form for each outcome of interest. We abstracted key
variables with regard to the study identifiers and con-
text, study design and limitations, intervention spe-
cifics and outcome effects. The quality of each study
was assessed and graded according to the CHERG
adaptation of the GRADE technique (‘GRADE
Profiler version 3.2’ scoring system) (Supplementary
Table a).
We summarized the evidence by outcome including
qualitative assessment of the quality of each specific
outcome (Supplementary Table b). In addition, for
any outcome with more than one study, a meta-
analysis was conducted and pooled relative risk and
corresponding 95% confidence interval (CI) reported
using the fixed-effect model (Mantel–Haenszel
method).8 In the case of heterogeneity (P< 0.1), the
random effect model (DerSimonian–Laird method)
was applied (although it is recognized that due to
the variation in precise interventions, study methods
and outcome definitions, the meta-estimates should
be interpreted cautiously). All analyses were con-
ducted using STATA 10.0 statistical software.
For the outcome of interest, namely the effect
of community case management with antibiotics,
oxygen treatment, zinc treatment and vitamin A treat-
ment on pneumonia mortality, we applied the CHERG
Rules for Evidence Review to the collective pneumo-
nia morbidity and mortality outcomes to generate a
final estimate for the reduction in pneumonia mortal-
ity (Supplementary Table c).
Results
Community case management
We identified 154 titles from the search conducted
in Medline, 87 from Embase and 62 from Web of
Knowledge. After elimination of duplicates, studies
with alternative outcome parameters, review articles
and studies that did not fit the inclusion criteria, a
total of 12 studies were extracted from the biblio-
graphic databases9–20 and two studies were identified
from a published meta-analysis21,22 (Supplementary
Figure S1). The characteristics of the studies that
were identified to estimate the effect of community
case management on pneumonia mortality are pre-
sented in Supplementary Table S4. A summary of
the identified outcomes as well as their exact defini-
tions are presented in Supplementary Table S5.
Two of the identified studies10,20 did not report
enough data, and therefore they were not included
in the meta-analyses. In addition, although four stu-
dies reported data on the effect of community case
management with antibiotics on incidence of moder-
ate/severe episodes of ALRI, a morbidity analysis was
not performed because the signs they used to identify
ALRI were either reported by the child’s mother,12,15
or were not based on the WHO classification (mild,
moderate, severe),17 or were not specified.9
In Table 1, we report the quality assessment of
studies by outcome, as well as results from corre-
sponding meta-analyses for the effect of community
case management with antibiotic treatment on
pneumonia-related outcomes. The summary effect of
community case management with antibiotic treat-
ment on ALRI mortality for children (i) 0–1-month-
old after summarizing four concurrent stu-
dies11,13,16,18 was 42% (95% CI 23–54%); (ii)
0–1-year-old after summarizing eight concurrent
11,14,16,18,19,22 and one before/after study17 was 42%
(95% CI 33–55%); (iii) 1–4 years old after summariz-
ing two before/after studies17,19 was 49% (95% CI  7
to 76%); and (iv) 0–5 years old after summarizing
seven concurrent11,13,14,16,18,19,22 and two before/after
studies9,17 was 35% (95% CI 18–48%) (Figure 1a). In
addition, the summary effect of community case
management with antibiotic treatment on all-cause
mortality for children: (i) 0–1 month old after sum-
marizing five concurrent studies11,13,14,16,18 was 27%
(95% CI 18–35%); (ii) 0–1 years old after summariz-
ing eight concurrent11,14,16,18,19,22 and one before/after
study17 was 21% (95% CI 14–28%); (iii) 1–4 years old
after summarizing two before/after studies was17,19
51% (95% CI 30–66%); and (iv) 0–5 years old after
summarizing eight concurrent11,13,14,16,18,19,21,22
and two before/after studies9,17 was 21% (95% CI
12–30%) (Table 1). According to the CHERG Rules 2
for Evidence Review in order to estimate the effect on
pneumonia mortality, we used the effect of commu-
nity case management with antibiotic treatment on
ALRI mortality of children 0–5 years old (Figure 1b).
Hospital case management
Antibiotic treatment for (very) severe pneumonia
We identified 476 titles from the search conducted in
Medline and 1241 from Embase. After elimination of
duplicates, studies with alternative outcome parame-
ters, review articles and studies that did not fit the
inclusion criteria, a total of ten studies were extracted
from the bibliographic databases23–32 (Supplementary
Figure S2a). These studies included two before/after
studies and observational data (large case series con-
ducted in a structured manner often as one arm of
a clinical trial) and reported mortality outcomes.
The characteristics of these studies are presented
in Supplementary Table S6. A summary of the identi-
fied outcomes as well as their exact definitions
are presented in Supplementary Table S7. We have
not reported observational studies that reported
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other treatment outcomes such as failure to improve,
need for change in antibiotic treatment or time to
reduction in respiratory rate since these were applied
in a non-standard manner that varied widely and had
not a clear relationship to risk of mortality.
The reduction of the case fatality rate after the
implementation of the WHO’s standard acute respira-
tory infection (ARI) case management guidelines was
23% (–100%, 70%) based on the results of two before/
after study.26,32 The summary case fatality rate of
antibiotics on severe pneumonia after summarizing
four studies (3945 episodes)28–31 was 0.6% (95% CI
0.4–0.9%) (Table 2 and Figure 2). These studies
were conducted in developing countries including
Columbia, Ghana, India, Mexico, Pakistan, South
Africa, Vietnam, Uruguay and Zambia (between
1991 and 2006). The reported case fatality rates
ranged from 0 to 1% and the antimicrobial agents
used to manage these children included oral amoxi-
cillin, oral co-trimoxazole, parenteral ampicillin,
parenteral penicillin and macrolides (Supplementary
Table S6). Some studies did not contain information
on co-interventions; however, where specified, these
included oxygen therapy, bronchodilators and anti-
pyretics when indicated (Supplementary Table S6).
The summary case fatality rates of antibiotics on
very severe pneumonia after summarizing four studies
(5376 episodes)23–27 were 6.5% (95% CI 4.3–9.6%)
(Table 2 and Figure 2). These studies were conducted
in developing countries including Bangladesh,
Ecuador, India, Pakistan, Papua New Guinea,
Mexico, South Africa, Yemen and Zambia (between
1979 and 2004). The reported case fatality rates
ranged from 2 to 19% and it is evident that case fatal-
ity rates were higher in children <12 months old than
in older children (Supplementary Table S6).
Oxygen treatment
We identified 213 titles from the search conducted in
Medline and 172 from Embase. After elimination of
Outcome Measures
Application of 
Standard Rules
ALRI specific mortality; concurrent and 
before/after; 0-4 years old; n=9; 4320 
events) Community case management 
with antibiotic treatment reduces ALRI 
mortality by 35% (18, 48%)
Rule 2: APPLY
All cause mortality; concurrent and 
before/after; 0-4 years old; n=10; 10866 
events) Community case management 
with antibiotic treatment reduces all cause 
mortality by 21% (12, 30%)
(a)
(b)
Figure 1 (a) Forrest plot for the effect of community case management with antibiotic treatment on ALRI mortality
(concurrent and before/after studies; children 0–5 years old). (b) Application of standardized rules for choice of final
outcome to estimate effect of community case management with antibiotic treatment for pneumonia.
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duplicates, studies with alternative outcome parame-
ters, review articles and studies that did not fit the
inclusion criteria, one study was extracted from the
bibliographic databases (Supplementary Figure S2b).
The characteristics of this study33 that were identified
to estimate the effect of oxygen therapy on pneumo-
nia mortality is presented in Supplementary Table S6.
The exact definition of the outcome is presented in
Supplementary Table S7. In Table 2, we report the
quality assessment of the study as well as the effect
of oxygen treatment on mortality for children with
pneumonia (35%, 95% CI 22–48%).
Treatment with zinc supplements
We identified 55 titles from the search conducted in
Medline and 153 from Embase. After elimination of
duplicates, studies with alternative outcome parame-
ters, review articles and studies that did not fit the
inclusion criteria, a total of five studies were extracted
Figure 2 Forrest plot of case fatality rates of antibiotic treatment for (very) severe pneumonia.
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from the bibliographic databases34–38 (Supplementary
Figure S2c). The characteristics of the studies that
were identified to estimate the effect of zinc supple-
mentation on pneumonia-related outcomes are pre-
sented in Supplementary Table S6. A summary of
the identified outcomes as well as their exact defini-
tions are presented in Supplementary Table S7.
In Table 2, we report the quality assessment of
studies by outcome, as well as results from corre-
sponding meta-analyses for the effect of zinc supple-
mentation treatment on pneumonia-related outcomes.
Of the four outcomes related to the duration of pneu-
monia symptoms, the effect size ranged from 17% for
hours to severe disease resolution (based on two
RCTs34,35) to 2% for hours to tachypnoea resolution
(based on four RCTs34,35,37,38). Since there were no
mortality data in order to estimate the effect on pneu-
monia mortality, we used the hours of hospitalization
effect based on the summary analysis of two RCTs34,35
[13% (37, 45%)] (according to the CHERG Rules for
Evidence Review. Since there is not clear evidence of
effect on pneumonia mortality this intervention
against pneumonia will not be included in the LiST
model) (Figure 3).
Treatment with vitamin A supplements
We identified 614 titles from the search conducted in
Medline and 1099 from Embase. After elimination of
duplicates, studies with alternative outcome parame-
ters, review articles and studies that did not fit the
inclusion criteria, a total of nine studies were extracted
from the bibliographic databases39–47 (Supplementary
Figure S2d). The characteristics of the studies that were
identified to estimate the effect of oxygen therapy on
pneumonia mortality are presented in Supplementary
Table S6. A summary of the identified outcomes
as well as their exact definitions are presented in
Supplementary Table S7.
In Table 2, we report the quality assessment of
studies by outcome, as well as results from corre-
sponding meta-analyses for the effect of vitamin A
supplementation treatment on pneumonia-related
outcomes. Although there was an estimate of mortal-
ity based on six studies39,41–45 [9% (95% CI 104 to
41%)], the specific outcome quality was very low
(since there were <50 total events) (Table 2).
Therefore, according to the CHERG Rules 0 and 5
for Evidence Review in order to estimate the effect
on pneumonia mortality, we used the summary
effect of vitamin A on days of hospitalization, which
was based on three studies39,45,46 (weighted mean dif-
ference 0.04 (95% CI 0.40 to 0.48). Since there is not
clear evidence of the effect on pneumonia mortality,
this intervention against pneumonia will not be
included in the LiST model) (Figure 4). Regarding
the other pneumonia-related outcomes, vitamin A
supplementation had no effect on either duration of
hypoxia resolution (weighted mean difference based
on four studies39,42–44 0.02 (95% CI 0.16 to 0.12))
or duration of tachypnoea resolution [weighted mean
difference based on five studies39,42–45 0.05 (95%
CI 0.21 to 0.31)] (Table 2).
Other supportive care
We were unable to identify controlled trials or
quasi-experimental studies or observational studies
that met our study criteria, which are reported on
the separate effect of supportive care interventions
Zinc; Pneumonia hospitalisation; RCT
.4 .87 2
 Combined
 Bose, India (2006)
 Brooks, Bangladesh (2004)
Figure 3 Forest plot for the effect of zinc supplementation for the treatment of pneumonia on the hours of hospitalization.
i166 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
such as fluid therapy, temperature control or clinical
monitoring on pneumonia mortality.
DISCUSSION
The estimates presented in this article represent a
systematic and structured review of the published
evidence of effectiveness of case management inter-
ventions for childhood pneumonia in developing
countries. The aim of this review was to inform the
LiST model and to make explicit the available
evidence.
The effect of case management in areas where HIV
is a major problem may substantially differ from the
estimates in regions where HIV is not such a problem.
The evidence presented in this review was generally
reported from areas in which HIV Acquired Immuno
Deficiency Syndrome (AIDS) was not a major public
health problem so this should be borne in mind when
interpreting the results. Further research is required
to provide data to model the effect in HIV-affected
regions, since there are data showing that HIV has
an impact on case fatality ratios (CFRs) in hospital
management and that pneumocystis pneumonia
(mainly found in HIV/AIDS patients) accounts for a
large proportion of these deaths.48
Another important issue is the rapidly changing cov-
erage with the new protein-polysaccharide conjugate
vaccines against Hib and pneumococcal disease. The
direct and indirect (herd immunity) effects of these
vaccines at moderate to high coverage are likely to
have a substantial impact on the major bacterial
pathogens causing pneumonia mortality and this
will necessitate a change in antibiotic treatment poli-
cies and will have an impact on the effect of case
management strategies on pneumonia mortality
impact. The studies reviewed in this report were con-
ducted in settings where these vaccines were not used
at all or not at a significant level of coverage.
Community case management with
antibiotic treatment
The effect of community case management on pneu-
monia mortality has been established by previous
reviews. However, there has been no previous attempt
to estimate the effect of the major child health inter-
ventions using a common approach or to consider
a wider range of case management interventions
against pneumonia.
This systematic review clearly highlights again the
effectiveness of community case management with
antibiotic treatment in reducing mortality from child-
hood pneumonia and reinforces the findings of previ-
ous reviews.5,6 A majority of these studies have been
carried out in Asia. This approach was effective even
in rural areas with very limited access to health ser-
vices and severely limited resources. However, it is
notable that despite the clear evidence in favour of
the effectiveness of this strategy first reviewed by
Sazawal et al.,5 community case management is still
not readily accessible in many populations with high
levels of child mortality.
Community case management models differ. On the
one hand, it might mean a proper assessment using
the Integrated Management of Childhood Illness
guidelines and antibiotics given by a nurse with 2–3
years of training in a well-setup primary government
or mission-run health clinic. On the other hand, it
might mean antibiotics given by a volunteer health
worker with as little as 2–6 weeks of training in a
village setting, with limited connection with the
formal health system.9,11,19,21,22 Recent programs con-
sidered are considering antibiotic treatment given at
home by a health worker for children with severe
pneumonia.28,49
Several studies emphasized the importance of active
case finding in reducing mortality levels although
once community awareness has been generated and
as maternal education develops within the commu-
nity, the use of active case finding may become grad-
ually less essential. It is suggested by these studies
that maternal education is an important factor in
the long-term success of the case management
approach. It is clear that good levels of health
worker supervision are needed for community case
management. Most of the trials evaluated community
case management in conjunction with other interven-
tions suggesting that integration of case management
into existing health systems will be essential to
achieve the greatest impact on childhood pneumonia
mortality. Ideally there should be a health system
continuum from community to primary care to
hospitals.
There are certain patient groups in which commu-
nity case management for pneumonia is more
Figure 4 Forest plot for the effect of vitamin A
supplementation for the treatment of pneumonia on
the days of hospitalization.
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complex and may not be appropriate. These groups
include children with very severe pneumonia, hypox-
aemia, neonates, malnourished children and children
with HIV. This systematic review is limited in that
it does not report studies that addressed these con-
textual issues or high-risk groups.
One issue for the effectiveness of the community
case management intervention is the coverage of the
antibiotic treatment, since not all children with pneu-
monia in these trials were identified and given anti-
biotic treatment. In the recent meta-analysis in 2003
by Sazawal et al.,6 the authors in corporation with the
principal investigators (PIs) of the trials conducted
a structured assessment of a number of aspects
related to the intervention intensity (intervention
score), including antibiotic availability, percentage of
detected cases, case treatment rates and treatment
compliance. They then conducted a meta-regression
that examined the correlation between intervention
effectiveness and intervention score and they reported
that community case management was more effective
against pneumonia in higher intervention intensity
studies.6 Although, the data used to construct the
intervention score represent qualitative rather than
quantitative views of the study PIs, they are consis-
tent with 50% of children with pneumonia receiving
the intervention as planned. It is therefore probable
that the impact on pneumonia mortality could have
been higher than that reported in the current and
previously published meta-analyses5,6 had a higher
proportion of children with pneumonia received the
intervention. Since the LiST tool is designed to
provide the effectiveness of an intervention on an
individual level, the meta-analysis estimate effect of
community case management will be adjusted to take
into consideration the 50% coverage of antibiotic
treatment (adjusted effectiveness 70%).
Other issues such as the emergence of antibiotic
resistance to simple oral antibiotics that can be pre-
scribed by community health workers, increasing
prevalence of HIV in a country or region and a
change in the main causes of pneumonia deaths fol-
lowing high coverage with Hib and pneumococcal
conjugate vaccines (discussed below) may necessitate
a re-appraisal of the effectiveness of the specific anti-
biotics recommended or, more widely, of how this
strategy is implemented.
Hospital antibiotic treatment
The current WHO guidelines for the acute manage-
ment of very severe pneumonia in resource-limited
settings recommend ampicillin and gentamicin for
up to 10 days, or alternatively, chloramphenicol
until improvement is seen. For pneumonia classified
as severe, amoxicillin or benzylpenicillin is recom-
mended for 55 days. This review was unable to iden-
tify any controlled trials, quasi-experimental studies
or observational studies from which treatment effec-
tiveness in reducing pneumonia mortality could be
estimated. The main reason for this is that WHO
(and other national paediatric and Ministry of
Health) treatment recommendations are widely
accepted and such studies would not be considered
ethical. One before/after study was identified that
reported a 52% reduction in case fatality rate in chil-
dren admitted with ARI after the implementation of
WHO’s standard ARI case management guidelines.32
In contrast, there were no significant differences in
CFR in another study before and after implementa-
tion of ARI case management guidelines.26 Reports of
very low CFRs for severe pneumonia and relatively
low CFR for very severe pneumonia are consistent
with a high level of effectiveness of hospital treat-
ment. However, it is not possible from published
data to quantify the precise effectiveness of hospital
treatment with antibiotics since there is no control
data available.
There is good general evidence that hospital care is
often deficient in many countries, including a study of
21 hospitals across seven countries in Asia and
Africa.50 Similar observations were made in a study
in Kenya, Tanzania, Solomon Islands, Kazakhstan,
Brazil, Angola and elsewhere.51–54 Attention to
improving quality of hospital care is therefore
required to ensure the appropriate, effective and
timely treatment is given.
Oxygen therapy
Hypoxaemia is a major complication and cause of
deterioration in pneumonia and is associated with a
significantly increased mortality risk. It is estimated
that 513% of children with severe pneumonia requir-
ing admission to health facilities have hypoxaemia,
and the prevalence rates are as high as 50% in some
hospitals.55 There are 11–20 million children each year
presenting to hospitals with pneumonia.3 This corre-
sponds to 1.5–2.7 million annual cases of hypoxaemic
pneumonia (13% prevalence).55
WHO-recommended treatment of severe pneumonia
includes oxygen therapy where oxygen saturation is
<90% (where pulse oximetry is available).56 This
review shows that there is now evidence that ensur-
ing ample supplies of oxygen and promoting a routine
and systematic approach of screening for hypoxaemia
using pulse oximetry is associated with reduced mor-
tality, and suggests that the technology required to do
so is sustainable and affordable in district hospitals in
developing countries. These findings are in accordance
with the results of a pilot study that was conducted in
one hospital (Goroka) and reported a 35–40% reduc-
tion in mortality with oxygen therapy.57 Regarding
the oxygen delivery methods, a recent Cochrane
review that summarized studies comparing oxygen
delivery methods (nasal prongs, nasopharyngeal
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catheters, nasal catheter, face mask, head box) found
no difference in treatment failure.58 However, more
research is required on the impact, cost and correct
implementation of effective technology in different
contexts, and on how to overcome barriers to access,
particularly in remote regions where power supplies
are unreliable. Further quasi-experimental studies,
e.g. with a stepped wedge introduction design would
provide more precise estimates of pneumonia mortal-
ity reduction in different settings.
Supportive care
This review was unable to identify any controlled
trials, quasi-experimental studies or observational stu-
dies that reported separately the effectiveness of dis-
crete supportive care interventions (a review of the
effectiveness of breastfeeding will be published sepa-
rately). Many supportive care interventions are rec-
ommended by WHO, national paediatric associations
and Ministries of Health in paediatric treatment
guidelines and are widely accepted but further
research is required to better define effective support-
ive care.
General issues related to case management
interventions
Any consideration of case management interventions
for pneumonia should recognize that weak infrastruc-
ture, shortage of essential supplies and, most of all,
the human resource crisis amongst health staff, espe-
cially in sub-Saharan Africa, are major factors limiting
the achievement of the mortality reduction effects
reported in these studies. In addition, risk factors
that are likely to affect pneumonia mortality such as
prevalence of bacterial aetiology, hypoxia, zinc defi-
ciency and measles prevalence, will differ between
different regions of the globe and therefore this will
affect the effectiveness of the interventions aiming to
the mentioned risk factors. Finally, community health
workers that are likely to deliver the community case
management interventions are most of the times not
linked to the formal health system of the country and
they are expected to work as volunteers. Addressing
issues such as drug supplies, equipment issues and
other supportive technology (such as oxygen sys-
tems), human resources, health financing, physical
facilities and infrastructure are essential elements
underlying the successful delivery of the interventions
reviewed here.
Conclusions
Following the CHERG guidelines we estimate that
community case management of pneumonia could
result in a 70% reduction in mortality from pneumo-
nia. In contrast, it is difficult to quantify the effective-
ness of hospital case management of severe and very
severe pneumonia with antibiotics due to the lack of
studies with a comparison group and therefore any
estimate will require a review of the available obser-
vational data coupled to expert opinion gathered
through a Delphi or a similar process. A single trial
of oxygen therapy suggests that this is effective in
reducing pneumonia mortality but further research
is required to give higher quality evidence so that
an effect estimate can be incorporated into the LiST
model. Finally, treatment of pneumonia episodes with
zinc and vitamin A were found to be ineffective in
reducing pneumonia mortality.
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KEY MESSAGES
 Results of the current review reinforce the evidence of the effectiveness of community and hospital
case management.
 Zinc and vitamin A supportive treatment does not affect pneumonia related outcomes in children.
 There is some evidence of an effect of oxygen therapy on pneumonia related outcomes but further
research is required.
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